Luyan Jiao
Vice President - New Drug Development Nuwacell
Seminars
Wednesday 9th September 2026
Advancing Hypoimmune iPSC‑Derived Dopaminergic Progenitors (NCR201) Toward Clinical Translation in Parkinson’s Disease
8:30 am
- Sharing early safety and tolerability insights from Nuwacell’s NCR201 Phase I/II trial
- Highlighting long-term efficacy and biological activity from investigator-initiated trials
- Building scalable CMC foundations aligned with NCR201’s accelerated development route
